Management of Myocardial Bridging
Initial Management Approach
- The European Society of Cardiology recommends beta-blockers as the first-line treatment for symptomatic myocardial bridging, which should be initiated in all patients with symptoms or evidence of ischemia 1, 2, 3.
- Beta-blockers work by reducing heart rate and myocardial contractility, which decreases systolic compression of the bridged coronary segment and prolongs diastole to improve coronary perfusion 1, 2, 3.
Risk Stratification and Diagnostic Evaluation
- The European Heart Journal suggests that ECG exercise testing, dobutamine stress echocardiography, or myocardial perfusion scintigraphy should be performed to evaluate for inducible ischemia in symptomatic patients 1, 2, 3.
- Coronary angiography visualizes the characteristic systolic compression of the vessel during the cardiac cycle, and can be used to assess the hemodynamic significance of the bridge 1, 2, 3.
Treatment Algorithm by Clinical Presentation
- The American College of Cardiology recommends that asymptomatic competitive athletes with incidental myocardial bridging can participate in all competitive sports without restriction 4.
- Beta-blockers remain the mainstay of initial therapy for symptomatic patients with proven ischemia 1, 2, 3.
- The American College of Cardiology advises restricting participation in competitive sports with high dynamic and static demands until symptoms resolve and stress testing normalizes 4.
Special Populations
- Myocardial bridging occurs in 30-50% of patients with hypertrophic cardiomyopathy, according to the European Heart Journal 1, 2, 3.
Critical Pitfalls to Avoid
- The European Heart Journal warns against prescribing nitrates for chest pain in myocardial bridging, as they paradoxically worsen systolic compression and symptoms 1, 2, 3.
- The American College of Cardiology advises against restricting asymptomatic individuals without clinical evidence of ischemia from vigorous activity, as there is no evidence supporting such restrictions 4.
Ongoing Monitoring
- The European Society of Cardiology recommends that patients should undergo periodic reassessment with stress testing to evaluate for residual ischemia, particularly after initiating or changing therapy 5.
Medical Management of Myocardial Bridging
First-Line Therapy: Beta-Blockers
- The European Society of Cardiology recommends metoprolol (extended-release metoprolol succinate preferred) as a first-line treatment for symptomatic myocardial bridging, with target dosing aimed at achieving a resting heart rate of 55-60 beats per minute 6
- The American Heart Association suggests carvedilol or bisoprolol as appropriate alternatives to metoprolol, particularly in patients with concurrent left ventricular dysfunction (LVEF ≤40%), where carvedilol may offer superior outcomes 7
- Beta-blockers with intrinsic sympathomimetic activity should be avoided as they are less effective for anti-ischemic purposes 7
Second-Line Therapy: Non-Dihydropyridine Calcium Channel Blockers
- The European Society of Cardiology recommends non-dihydropyridine calcium channel blockers (diltiazem or verapamil) as a second-line option for patients who are contraindicated to beta-blockers or have persistent symptoms despite adequate beta-blockade 6
- Diltiazem and verapamil slow heart rate and reduce myocardial contractility through AV nodal effects and negative inotropy, similar to beta-blockers 8